Key clinical point: Shifts in the epidemiology and treatment of hepatitis C have made universal one-time screening cost effective.
Major finding: Universal one-time screening is now cost effective as long as the prevalence of hepatitis C virus infection exceeds 0.07% in individuals born outside the high-prevalence birth cohort (1945-1965).
Study details: A Markov state transition model based on quality-adjusted life-years and U.S. dollars.
Disclosures: Partial funding came from the National Foundation for the Centers for Disease Control and Prevention (CDC Foundation), with funding provided through multiple donors to the CDC Foundation’s Viral Hepatitis Action Coalition. Dr. Eckman reported receiving grant support from Merck and one coinvestigator reported ties to AbbVie, Gilead, Merck, and several other pharmaceutical companies.
Eckman MH et al. Clin Gastroenterol Hepatol. 2018 Sep 7..